Welcome to LookChem.com Sign In|Join Free
  • or

Encyclopedia

Edonerpic

Base Information Edit
  • Chemical Name:Edonerpic
  • CAS No.:519187-23-6
  • Molecular Formula:C16H21NO2S
  • Molecular Weight:291.414
  • Hs Code.:
  • UNII:QY49O94S2W
  • Nikkaji Number:J2.972.359A
  • Wikidata:Q27287558
  • NCI Thesaurus Code:C174903
  • Metabolomics Workbench ID:149593
  • ChEMBL ID:CHEMBL4302089
  • Mol file:519187-23-6.mol
Edonerpic

Synonyms:Edonerpic;519187-23-6;T-817;Edonerpic [INN];1-(3-(2-(Benzo[b]thiophen-5-yl)ethoxy)propyl)azetidin-3-ol;Edonerpic [WHO-DD];QY49O94S2W;J2.972.359A;1-[3-[2-(1-benzothiophen-5-yl)ethoxy]propyl]azetidin-3-ol;3-Azetidinol, 1-[3-(2-benzo[b]thien-5-ylethoxy)propyl]-;3-Azetidinol, 1-(3-(2-benzo(b)thien-5-ylethoxy)propyl)-;1-(3-(2-(Benzo(b)thiophen-5-yl)ethoxy)propyl)azetidin-3-ol;1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}azetidin-3-ol;edonerpic-maleate;Edonerpic [INN:WHO-DD];UNII-QY49O94S2W;SCHEMBL27725;CHEMBL4302089;HQNACSFBDBYLJP-UHFFFAOYSA-N;EX-A4553;MFCD28502068;AKOS027337120;DB05938;P14964;A901341;Q27287558;1-(3-(2-(1-benzothiophene-5-yl)ethoxy)propyl)-3-azetidinol;1-(3-[2-(1-benzothiophen-5-yl)ethoxy]propyl) azetidin-3-ol;1-[3-[2-(1-Benzothiophene-5-yl)ethoxy]propyl]azetidine-3-ol;1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol

Suppliers and Price of Edonerpic
Supply Marketing:Edit
Business phase:
The product has achieved commercial mass production*data from LookChem market partment
Manufacturers and distributors:
  • Manufacture/Brand
  • Chemicals and raw materials
  • Packaging
  • price
Total 5 raw suppliers
Chemical Property of Edonerpic Edit
Chemical Property:
  • XLogP3:2.6
  • Hydrogen Bond Donor Count:1
  • Hydrogen Bond Acceptor Count:4
  • Rotatable Bond Count:7
  • Exact Mass:291.12930009
  • Heavy Atom Count:20
  • Complexity:296
Purity/Quality:

97% *data from raw suppliers

Safty Information:
  • Pictogram(s):  
  • Hazard Codes: 
MSDS Files:
Useful:
  • Canonical SMILES:C1C(CN1CCCOCCC2=CC3=C(C=C2)SC=C3)O
  • Recent EU Clinical Trials:A Phase 2 multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer’s Disease or mild Alzheimer’s Disease.
  • Recent NIPH Clinical Trials:A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study of T-817MA in Post-stroke Patients Undergoing Rehabilitation for Upper Limb Hemiplegia
Post RFQ for Price